NEXALIN TECHNOLOGY IN

Nexalin Technology CEO Provides Letter to Shareholders

10 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

09 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

04 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

02 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

28 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

14 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

13 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

08 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

23 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Unveils Next-Generation HALO™ Clarity

11 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

18 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

25 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

16 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

07 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

03 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

26 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

10 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region

01 Jun 2023 08:30:00 By Nasdaq GlobeNewswire